Bharat Biotech Gets CDSCO Panel Nod To Manufacture Rotavirus Vaccine Live Attenuated, Oral
New Delhi: The vaccine major Bharat Biotech has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture a Rotavirus Vaccine (Live Attenuated, Oral) (antibiotic-free).
This came after Bharat Biotech presented its proposal for a grant of manufacturing permission for the Rotavirus Vaccine (Live Attenuated, Oral) (antibiotic-free).
Rotavirus commonly causes severe, watery diarrhea and vomiting in infants and young children. Children may become dehydrated and need to be hospitalized and can even die. There are nine species of rotavirus, referred to as A, B, C, D, F, G, H, I, and J. Humans are primarily infected by the species Rotavirus A.
Rotavirus primarily infects enterocytes and induces diarrhea through the destruction of absorptive enterocytes (leading to malabsorption), intestinal secretion stimulated by rotavirus non-structural protein, and activation of the enteric nervous system.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.